<script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app17.us.archive.org';v.server_ms=390;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include --><!-- BEGIN WAYBACK TOOLBAR INSERT -->
<script type="text/javascript" src="/static/js/timestamp.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/graph-calc.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/auto-complete.js?v=1531166943.0" charset="utf-8"></script>
<script type="text/javascript" src="/static/js/toolbar.js?v=1531166943.0" charset="utf-8"></script>

<style type="text/css">
body {
  margin-top:0 !important;
  padding-top:0 !important;
  /*min-width:800px !important;*/
}
.wb-autocomplete-suggestions {
    text-align: left; cursor: default; border: 1px solid #ccc; border-top: 0; background: #fff; box-shadow: -1px 1px 3px rgba(0,0,0,.1);
    position: absolute; display: none; z-index: 2147483647; max-height: 254px; overflow: hidden; overflow-y: auto; box-sizing: border-box;
}
.wb-autocomplete-suggestion { position: relative; padding: 0 .6em; line-height: 23px; white-space: nowrap; overflow: hidden; text-overflow: ellipsis; font-size: 1.02em; color: #333; }
.wb-autocomplete-suggestion b { font-weight: bold; }
.wb-autocomplete-suggestion.selected { background: #f0f0f0; }
</style>
<div id="wm-ipp" lang="en" style="display:none;direction:ltr;">
<div style="position:fixed;left:0;top:0;right:0;">
<div id="wm-ipp-inside">
  <div style="position:relative;">
    <div id="wm-logo" style="float:left;width:130px;padding-top:10px;">
      <a href="/web/" title="Wayback Machine home page"><img src="/static/images/toolbar/wayback-toolbar-logo.png" alt="Wayback Machine" width="110" height="39" border="0" /></a>
    </div>
    <div class="r" style="float:right;">
      <div id="wm-btns" style="text-align:right;height:25px;">
                  <div id="wm-save-snapshot-success">success</div>
          <div id="wm-save-snapshot-fail">fail</div>
          <a href="#"
             onclick="__wm.saveSnapshot('https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml', '20171002233911')"
             title="Share via My Web Archive"
             id="wm-save-snapshot-open"
          >
            <span class="iconochive-web"></span>
          </a>
          <a href="https://archive.org/account/login.php"
             title="Sign In"
             id="wm-sign-in"
          >
            <span class="iconochive-person"></span>
          </a>
          <span id="wm-save-snapshot-in-progress" class="iconochive-web"></span>
        	<a href="http://faq.web.archive.org/" title="Get some help using the Wayback Machine" style="top:-6px;"><span class="iconochive-question" style="color:rgb(87,186,244);font-size:160%;"></span></a>
	<a id="wm-tb-close" href="#close" onclick="__wm.h(event);return false;" style="top:-2px;" title="Close the toolbar"><span class="iconochive-remove-circle" style="color:#888888;font-size:240%;"></span></a>
      </div>
      <div id="wm-share" style="text-align:right;">
	<a href="#" onclick="window.open('https://www.facebook.com/sharer/sharer.php?u=https://web.archive.org/web/20171002233911/https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml', '', 'height=400,width=600'); return false;" title="Share on Facebook" style="margin-right:5px;" target="_blank"><span class="iconochive-facebook" style="color:#3b5998;font-size:160%;"></span></a>
	<a href="#" onclick="window.open('https://twitter.com/intent/tweet?text=https://web.archive.org/web/20171002233911/https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml&amp;via=internetarchive', '', 'height=400,width=600'); return false;" title="Share on Twitter" style="margin-right:5px;" target="_blank"><span class="iconochive-twitter" style="color:#1dcaff;font-size:160%;"></span></a>
      </div>
    </div>
    <table class="c" style="">
      <tbody>
	<tr>
	  <td class="u" colspan="2">
	    <form target="_top" method="get" action="/web/submit" name="wmtb" id="wmtb"><input type="text" name="url" id="wmtbURL" value="https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml" onfocus="this.focus();this.select();" /><input type="hidden" name="type" value="replay" /><input type="hidden" name="date" value="20171002233911" /><input type="submit" value="Go" /></form>
	  </td>
	  <td class="n" rowspan="2" style="width:110px;">
	    <table>
	      <tbody>
		<!-- NEXT/PREV MONTH NAV AND MONTH INDICATOR -->
		<tr class="m">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930202656/https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml" title="30 Sep 2016"><strong>Sep</strong></a></td>
		  <td class="c" id="displayMonthEl" title="You are here: 23:39:11 Oct 02, 2017">OCT</td>
		  <td class="f" nowrap="nowrap">Nov</td>
		</tr>
		<!-- NEXT/PREV CAPTURE NAV AND DAY OF MONTH INDICATOR -->
		<tr class="d">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930202656/https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml" title="20:26:56 Sep 30, 2016"><img src="/static/images/toolbar/wm_tb_prv_on.png" alt="Previous capture" width="14" height="16" border="0" /></a></td>
		  <td class="c" id="displayDayEl" style="width:34px;font-size:24px;white-space:nowrap;" title="You are here: 23:39:11 Oct 02, 2017">02</td>
		  <td class="f" nowrap="nowrap"><img src="/static/images/toolbar/wm_tb_nxt_off.png" alt="Next capture" width="14" height="16" border="0" /></td>
		</tr>
		<!-- NEXT/PREV YEAR NAV AND YEAR INDICATOR -->
		<tr class="y">
		  <td class="b" nowrap="nowrap"><a href="https://web.archive.org/web/20160930202656/https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml" title="30 Sep 2016"><strong>2016</strong></a></td>
		  <td class="c" id="displayYearEl" title="You are here: 23:39:11 Oct 02, 2017">2017</td>
		  <td class="f" nowrap="nowrap">2018</td>
		</tr>
	      </tbody>
	    </table>
	  </td>
	</tr>
	<tr>
	  <td class="s">
	    	    <div id="wm-nav-captures">
	      	      <a class="t" href="/web/20171002233911*/https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml" title="See a list of every capture for this URL">2 captures</a>
	      <div class="r" title="Timespan for captures of this URL">30 Sep 2016 - 02 Oct 2017</div>
	      </div>
	  </td>
	  <td class="k">
	    <a href="" id="wm-graph-anchor">
	      <div id="wm-ipp-sparkline" title="Explore captures for this URL" style="position: relative">
		<canvas id="wm-sparkline-canvas" width="575" height="27" border="0"></canvas>
	      </div>
	    </a>
	  </td>
	</tr>
      </tbody>
    </table>
    <div style="position:absolute;bottom:0;right:2px;text-align:right;">
      <a id="wm-expand" class="wm-btn wm-closed" href="#expand" onclick="__wm.ex(event);return false;"><span id="wm-expand-icon" class="iconochive-down-solid"></span> <span style="font-size:80%">About this capture</span></a>
    </div>
  </div>
    <div id="wm-capinfo" style="border-top:1px solid #777;display:none; overflow: hidden">
            <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center">COLLECTED BY</div>
    <div style="padding:3px;position:relative" id="wm-collected-by-content">
            <div style="display:inline-block;vertical-align:top;width:50%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Partner-593);"></span>
		Organization: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Partner-593" target="_new"><span class="wm-title">Government Printing Office</span></a>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  Archive-It Partner 593: Government Printing Office
	</div>
	      </div>
      <div style="display:inline-block;vertical-align:top;width:49%;">
			<span class="c-logo" style="background-image:url(https://archive.org/services/img/ArchiveIt-Collection-5265)"></span>
		<div>Collection: <a style="color:#33f;" href="https://archive.org/details/ArchiveIt-Collection-5265" target="_new"><span class="wm-title">National Guideline Clearinghouse</span></a></div>
		<div style="max-height:75px;overflow:hidden;position:relative;">
	  <div style="position:absolute;top:0;left:0;width:100%;height:75px;background:linear-gradient(to bottom,rgba(255,255,255,0) 0%,rgba(255,255,255,0) 90%,rgba(255,255,255,255) 100%);"></div>
	  NGC is an initiative of the Agency for Healthcare Research and Quality (AHRQ) External Web Site Policy, U.S. Department of Health and Human Services. NGC was originally created by AHRQ in partnership with the American Medical Association and the American Association of Health Plans (now America's Health Insurance Plans [AHIP]).

The NGC mission is to provide physicians and other health professionals, health care providers, health plans, integrated delivery systems, purchasers, and others an accessible mechanism for obtaining objective, detailed information on clinical practice guidelines and to further their dissemination, implementation, and use.
	</div>
	      </div>
    </div>
    <div style="background-color:#666;color:#fff;font-weight:bold;text-align:center" title="Timestamps for the elements of this page">TIMESTAMPS</div>
    <div>
      <div id="wm-capresources" style="margin:0 5px 5px 5px;max-height:250px;overflow-y:scroll !important"></div>
      <div id="wm-capresources-loading" style="text-align:left;margin:0 20px 5px 5px;display:none"><img src="/static/images/loading.gif" alt="loading" /></div>
    </div>
  </div></div></div></div><script type="text/javascript">
__wm.bt(575,27,25,2,"web","https://www.guideline.gov/summaries/downloadcontent/ngc-10599?contentType=xml","2017-10-02",1996);
</script>
<!-- END WAYBACK TOOLBAR INSERT --><version>
  <xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource>
  <section secid="390" ordby="100" name="General">
    <field fieldid="161" ordby="105" id="391" name="Guideline Title" type="text">
      <fieldvalue value="<div class=&quot;content_title&quot;>Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach.</div>"/>
    </field>
    <field fieldid="97" ordby="110" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Frazier DM, Allgeier C, Homer C, Marriage BJ, Ogata B, Rohr F, Splett PL, Stembridge A, Singh RH. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metab. 2014 Jul;112(3):210-7. [72 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24881969&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="120" ordby="115" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>"/>
    </field>
  </section>
  <section secid="420" ordby="300" name="Recommendations">
    <field fieldid="151" ordby="310" id="421" name="Major Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Definitions for the quality of the evidence (<strong>A-E</strong>) and the strength of the recommendation (<strong>I, II</strong>) are provided at the end of the &quot;Major Recommendations&quot; field.</p>
<p><strong>Acute Dietary Treatment</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Provide aggressive nutrition management during illness or at first presentation to prevent or reverse catabolism and promote anabolism by supplying: adequate energy (up to 150% of usual energy intake); branched chain amino acids (BCAA)-free protein (increased to replace BCAA-containing intact protein); fluid (up to 150 mL/kg with careful monitoring of electrolytes and possible cerebral edema); and electrolytes and insulin (if needed). (<strong>B.I</strong>) </li>
    <li>Use parenteral nutrition alone (providing BCAA-free amino acids, lipids and/or glucose) or in conjunction with enteral feedings, when necessary to meet energy needs in severe illness. (<strong>B.II</strong>) </li>
    <li>Include nutritional intervention when dialysis, hemoperfusion or similar treatment is necessary to lower plasma BCAA and remove toxic metabolites. (<strong>C.II</strong>) </li>
    <li>Monitor BCAA, acid&amp;ndash;base balance, urine &amp;alpha;-ketoacids, blood glucose and clinical symptoms closely during illness. If hemofiltration or dialysis is necessary, blood gas, hematocrit, total protein, sodium, calcium, phosphorus, urea, and creatinine should also be monitored. (<strong>B.I</strong>) </li>
    <li>Add isoleucine (ILE) and valine (VAL), even if they are already in the 200&amp;ndash;400 &amp;mu;mol/L range, to help lower elevated plasma leucine (LEU) into the treatment range. (<strong>B.II</strong>) </li>
    <li>Reintroduce intact protein (or complete amino acid mixtures) when elevated plasma LEU approaches the upper limit of the treatment range: 200 &amp;mu;mol/L for infants and children &amp;le;5 years of age; and 300 &amp;mu;mol/L for individuals &amp;gt;5 years of age. (<strong>B.I</strong>) </li>
    <li>Consider use of breast milk (mean LEU concentration of 1 mg/mL) as a source of intact protein (and BCAA) in the dietary management of infants with maple syrup urine disease (MSUD) if there is frequent anthropometric, clinical, and laboratory monitoring of the infant and mother has adequate milk production. (<strong>D.I</strong>) </li>
    <li>Manage mild illnesses with patient-specific sick-day instructions to include reduction of intact protein by 50% to 100% for 24 to 48 hours by replacement with additional BCAA-free medical food, adequate hydration, addition of non-protein energy sources, and close monitoring. (<strong>D.II</strong>) </li>
</ol>
<p><strong>Achieving Appropriate BCAA Blood Concentrations</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Maintain plasma LEU concentrations, with frequent monitoring, between 75 and 200 &amp;mu;mol/L for infants and children &amp;le;5 years old and between 75 and 300 &amp;mu;mol/L for individuals &amp;gt;5 years of age to achieve favorable cognitive outcomes. (<strong>B.I</strong>) </li>
    <li>Maintain plasma ILE and VAL concentrations, with frequent monitoring, between 200 and 400 &amp;mu;mol/L (or slightly above the normal ranges) in all individuals to avoid metabolic instability and BCAA deficiencies. (<strong>B.I</strong>) </li>
    <li>Employ MSUD-specific dietary management strategies to achieve recommended BCAA concentrations. (<strong>A.I</strong>) (see Tables 3 and 4 in the original guideline document). </li>
    <li>Maintain plasma BCAA within the recommended ranges throughout life. (<strong>C.II</strong>) </li>
</ol>
<p><strong>Thiamin Supplementation</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Perform a thiamin challenge for all individuals with MSUD except those known to be homozygous for the 1312T&amp;gt;A mutation or other mutations resulting in less than 3% branched-chain &amp;alpha;-ketoacid dehydrogenase (BCKD) enzyme activity. (<strong>B.II</strong>) </li>
    <li>Initiate a thiamin challenge with a dosage of 50&amp;ndash;200 mg/day. (<strong>C.I</strong>) </li>
    <li>Evaluate response to thiamin challenge over a one month period by assessing plasma BCAA and/or tolerance for dietary BCAA. (<strong>D.II</strong>) </li>
    <li>Maintain thiamin supplementation and appropriate dietary BCAA restriction in thiamin-responsive individuals. (<strong>D.II</strong>) </li>
</ol>
<p><strong>Pregnancy and Postnatal Period in Women with MSUD</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Monitor closely and provide individualized dietary guidance to assure that intake is adequate to meet the increased protein, BCAA and energy requirements of pregnancy. (<strong>B.I</strong>) </li>
    <li>Maintain plasma BCAA concentrations in the normal (MSUD) treatment range (LEU: 75&amp;ndash;300 &amp;mu;mol/L; ILE and VAL: 200&amp;ndash;400 &amp;mu;mol/L) throughout pregnancy. (<strong>B.I</strong>) </li>
    <li>Treat pregnancy-related poor appetite, nausea and vomiting aggressively to prevent or minimize endogenous protein catabolism. See treatment strategies to prevent endogenous catabolism in Research Question 1 (see the &quot;Description of Methods Used to Collect/Select the Evidence&quot; field). (<strong>A.I</strong>) </li>
    <li>Evaluate the need for vitamin and/or mineral supplementation based on the pregnant woman's prescribed medical food, dietary adherence and laboratory assessment. (<strong>D.II</strong>) </li>
    <li>Pay special attention to the prevention of catabolism during particularly vulnerable periods of labor/delivery and the first two weeks postpartum, as well as up to six weeks postpartum. (<strong>C.I</strong>) </li>
    <li>Provide increased nutrient intake and close clinical and biochemical monitoring for the woman with MSUD who is breastfeeding. (<strong>D.I</strong>) </li>
</ol>
<p><strong>Liver Transplantation in Individuals with MSUD</strong></p>
<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Consider liver transplantation as a viable treatment option for individuals with MSUD. (<strong>B.II</strong>) </li>
    <li>Attempt to bring candidates for liver transplant into good metabolic control (prior to surgery) through dietary management of BCAA. (<strong>C.II</strong>) </li>
    <li>Prevent metabolic decompensation in the perioperative period. (<strong>B.I</strong>) </li>
    <li>Allow relaxation of the BCAA-restricted diet and lift precautions for severe metabolic decompensation for individuals with MSUD who have had successful liver transplantation. (<strong>C.I</strong>) </li>
    <li>Provide nutrition counseling to assist in dietary transition, and monitor the anthropometric and nutritional status of individuals with MSUD who have had successful liver transplantation. (<strong>E.II</strong>) </li>
</ol>
<p><strong><span style=&quot;text-decoration: underline;&quot;>Definitions</span></strong>:</p>
<p><strong>Recommendation Ratings and Application</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Recommendation Ratings and Application&quot;>
    <tbody>
        <tr>
            <th valign=&quot;top&quot; colspan=&quot;3&quot;>Recommendation Rating</th>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot; style=&quot;width: 5%;&quot;>A</td>
            <td valign=&quot;top&quot;>Strong</td>
            <td valign=&quot;top&quot;>The benefits clearly exceed the harms (or the harms clearly exceed the benefits in the case of a strong negative recommendation); and the quality of the supporting evidence is excellent/good. In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>B</td>
            <td valign=&quot;top&quot;>Fair</td>
            <td valign=&quot;top&quot;>The benefits exceed the harms (or the harms clearly exceed the benefits in the case of a negative recommendation), but the quality of evidence is not as strong as &quot;A&quot;. In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>C</td>
            <td valign=&quot;top&quot;>Weak</td>
            <td valign=&quot;top&quot;>The quality of evidence that exists is suspect or well-done studies show little clear advantage for one recommendation over another.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>D</td>
            <td valign=&quot;top&quot;>Consensus</td>
            <td valign=&quot;top&quot;>Expert opinion supports the recommendation even though the available scientific evidence did not present consistent results, or controlled trials were lacking.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>E</td>
            <td valign=&quot;top&quot;>Insufficient Evidence</td>
            <td valign=&quot;top&quot;>There is a lack of pertinent evidence and this may be due to an unclear balance between benefits and harms.</td>
        </tr>
        <tr>
            <th valign=&quot;top&quot; colspan=&quot;3&quot;>Clinical Action/Application</th>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>I</td>
            <td valign=&quot;top&quot;>Imperative</td>
            <td valign=&quot;top&quot;>The recommendation is broadly applicable to the target population without conditions. An imperative recommendation can be stated in &quot;require,&quot; or &quot;must,&quot; or &quot;should achieve certain goals&quot; terminology.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>II</td>
            <td valign=&quot;top&quot;>Conditional</td>
            <td valign=&quot;top&quot;>The recommendation clearly defines a specific situation that limits its applicability. A conditional recommendation can be stated in &quot;if/then&quot; terminology.</td>
        </tr>
    </tbody>
</table>
<p class=&quot;Note&quot;>Adapted for this guideline from: American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 2004; 114(3):874&amp;ndash;7.</p></div>"/>
    </field>
    <field fieldid="138" ordby="330" id="423" name="Clinical Algorithm(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>None provided</p></div>"/>
    </field>
  </section>
  <section secid="396" ordby="400" name="Scope">
    <field fieldid="140" ordby="405" id="397" name="Disease/Condition(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Maple syrup urine disease (MSUD)</p></div>"/>
    </field>
    <field fieldid="103" ordby="410" id="398" name="Guideline Category" type="picklist-many">
      <fieldvalue value="Management"/>
      <fieldvalue value="Treatment"/>
    </field>
    <field fieldid="113" ordby="415" id="399" name="Clinical Specialty" type="picklist-many">
      <fieldvalue value="Emergency Medicine"/>
      <fieldvalue value="Family Practice"/>
      <fieldvalue value="Internal Medicine"/>
      <fieldvalue value="Nephrology"/>
      <fieldvalue value="Neurology"/>
      <fieldvalue value="Nutrition"/>
      <fieldvalue value="Obstetrics and Gynecology"/>
      <fieldvalue value="Pediatrics"/>
      <fieldvalue value="Urology"/>
    </field>
    <field fieldid="114" ordby="420" id="400" name="Intended Users" type="picklist-many">
      <fieldvalue value="Advanced Practice Nurses"/>
      <fieldvalue value="Dietitians"/>
      <fieldvalue value="Health Care Providers"/>
      <fieldvalue value="Nurses"/>
      <fieldvalue value="Pharmacists"/>
      <fieldvalue value="Physician Assistants"/>
      <fieldvalue value="Physicians"/>
    </field>
    <field fieldid="129" ordby="425" id="401" name="Guideline Objective(s)" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>To foster optimum nutrition management of individuals with maple syrup urine disease (MSUD) and reduce the uncertainty and variability in the management of this inherited metabolic disorder (IMD)</p></div>"/>
    </field>
    <field fieldid="132" ordby="430" id="402" name="Target Population" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Individuals with maple syrup urine disease (MSUD) at all life stages from the acute newborn period, through childhood and adolescence, to ongoing management in the adult years and during pregnancy</p></div>"/>
    </field>
    <field fieldid="133" ordby="435" id="403" name="Interventions and Practices Considered" type="text">
      <fieldvalue value="<ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;>
    <li>Specialized nutrition management throughout life </li>
    <li>Aggressive nutrition management during acute illness/sickness </li>
    <li>Achieving and maintaining appropriate plasma branched chain amino acid (BCAA) concentrations </li>
    <li>Thiamin supplementation </li>
    <li>Monitoring pregnancy and postnatal period </li>
    <li>Liver transplantation </li>
</ol>"/>
    </field>
    <field fieldid="134" ordby="440" id="404" name="Major Outcomes Considered" type="text">
      <fieldvalue value="<ul style=&quot;list-style-type: disc;&quot;>
    <li>Quality of life </li>
    <li>Adverse outcomes </li>
    <li>Appropriate growth and health maintenance </li>
    <li>Neurocognitive development </li>
</ul>"/>
    </field>
  </section>
  <section secid="405" ordby="500" name="Methodology">
    <field fieldid="109" ordby="505" id="406" name="Methods Used to Collect/Select the Evidence" type="picklist-many">
      <fieldvalue value="Hand-searches of Published Literature (Primary Sources)"/>
      <fieldvalue value="Hand-searches of Published Literature (Secondary Sources)"/>
      <fieldvalue value="Searches of Electronic Databases"/>
      <fieldvalue value="Searches of Unpublished Data"/>
    </field>
    <field fieldid="135" ordby="510" id="407" name="Description of Methods Used to Collect/Select the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Search Process</strong></p>
<p>Because of the known scarcity of peer-reviewed scientific literature in nutrition management of inherited metabolic disorders (IMDs), the search process included both published scientific studies and gray, or practice, literature.</p>
<p>For the peer-reviewed literature, medical subject heading (MeSH) terms were specific to each question, but inclusion and exclusion criteria were the same for all questions (see questions below). Eligibility for research questions was limited to human studies and published in English from 1985 to summer 2011 (except for the research question related to thiamin that used earlier references from 1971), with nutrition data included. There were no study-design, age or setting restrictions. PubMed was the primary database used. Searches were conducted by a research librarian. The titles and abstracts of identified articles were scanned for relevance and matched with inclusion/exclusion criteria by the workgroup. Excluded articles were noted and qualifying articles were gathered for review and abstracting. Reference lists within the identified articles were examined for additional resources. These were added if they contributed pertinent information.</p>
<p>Practice (or gray) literature sources, which are not accessible through standard search systems, include abstracts and presentations from scientific and practice-based meetings, clinical protocols and guidelines, unpublished research, communication among experts (including list-serves), professional newsletters, and book chapters. The search for gray literature involved requests to individuals (e.g., practitioners and researchers) and organizations through their professional list serves, as well as online searches for materials related to nutrition and maple syrup urine disease (MSUD). Identified resources were screened and prioritized for inclusion based on relevance and substantive information not available in scientific literature, and currency.</p>
<p><strong>Question 1</strong>: For the individual with MSUD or suspected MSUD, what nutritional interventions must be initiated during illness, trauma or surgery to achieve optimal outcomes?</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li><strong>Search Terms</strong>: MSUD or maple syrup urine disease, or branched chain alpha keto acid dehydrogenase deficiency, or BCKAD deficiency AND treatment, or management, or symptoms, or dialysis </li>
    <li><strong>Date of Literature Search Request</strong>: June 1, 2011 </li>
</ul>
<p><strong>Question 2</strong>: For the individual with MSUD treated through dietary modification, what are BCAA blood levels that lead to optimal nutritional, medical and quality of life outcomes?</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li><strong>Search Terms</strong>: MSUD or maple syrup urine disease, or inborn errors of metabolism or branched chain alpha keto acid dehydrogenase deficiency. BCKAD deficiency, AND leucine, or branched chain amino acids, or outcome, or monitoring </li>
    <li><strong>Date of Literature Search Request</strong>: June 1, 2011 </li>
</ul>
<p><strong>Question 3</strong>: For the individual with MSUD, what is the most effective method for initiating, dosing and evaluating response to thiamin supplementation?</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li><strong>Search Terms</strong>: MSUD or maple syrup urine disease, or inborn errors of metabolism or branched chain alpha keto acid dehydrogenase deficiency. BCKAD deficiency, or aminoacidopathies AND thiamin, or thiamine, or thiamin response, or thiamin responsivity, or thiamin challenge, or thiamin supplementation, or thiamin activation, or thiamine pyrophosphate, or treatment </li>
    <li><strong>Date of Literature Search Request</strong>: June 1, 2011 </li>
</ul>
<p><strong>Question 4</strong>: For the woman with MSUD, what specific nutritional interventions must be initiated during pregnancy, at delivery and during the postpartum period to achieve optimal outcomes for her and her newborn infant?</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li><strong>Search Terms</strong>: MSUD or maple syrup urine disease, or inborn errors of metabolism or branched chain alpha keto acid dehydrogenase deficiency, or BCKAD deficiency, or maternal MSUD AND pregnancy, or labor and delivery, or pregnancy complications </li>
    <li><strong>Date of Literature Search Request</strong>: June 1, 2011 </li>
</ul>
<p><strong>Question 5</strong>: For the individual with MSUD undergoing liver transplantation, what specific nutritional interventions result in optimal nutritional, medical and quality of life outcomes?</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li><strong>Search Terms</strong>: MSUD or maple syrup urine disease, or inborn errors of metabolism or branched chain alpha keto acid dehydrogenase deficiency. BCKAD deficiency, AND liver transplant, AND transplant outcome, or long term outcome, or complications, or treatment, or nutrition </li>
    <li><strong>Date of Literature Search Request</strong>: June 1, 2011 </li>
</ul></div>"/>
    </field>
    <field fieldid="136" ordby="515" id="408" name="Number of Source Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Number of studies initially identified: 229</p>
<p>Number of studies included: 98</p></div>"/>
    </field>
    <field fieldid="115" ordby="520" id="409" name="Methods Used to Assess the Quality and Strength of the Evidence" type="picklist-choice">
      <fieldvalue value="Weighting According to a Rating Scheme (Scheme Not Given)"/>
    </field>
    <field fieldid="149" ordby="525" id="410" name="Rating Scheme for the Strength of the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not stated</p></div>"/>
    </field>
    <field fieldid="116" ordby="530" id="411" name="Methods Used to Analyze the Evidence" type="picklist-many">
      <fieldvalue value="Systematic Review with Evidence Tables"/>
    </field>
    <field fieldid="150" ordby="535" id="412" name="Description of the Methods Used to Analyze the Evidence" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Critical Appraisal and Abstraction</strong></p>
<p>Each scientific article was critically reviewed by a trained analyst using a Quality Criteria Checklist, and the study design and methodology, findings, and author's conclusions were abstracted to Evidence Abstract Worksheets. Quality criteria addressed subjects' and control groups' selection and retention, intervention clearly described and followed, other intervening variables tracked, outcomes defined, measures validated, and appropriate statistical analysis. Based on the number of criteria met, each article was assigned a quality rating of positive, neutral or negative.</p>
<p>Practice resources were reviewed by workgroup members using a specially developed quality criteria checklist for gray literature that included the following: clear purpose, relevance to intended users, systematic development process, and clear clinical recommendations, applicable to practice, and free of conflict of interest.</p></div>"/>
    </field>
    <field fieldid="112" ordby="540" id="413" name="Methods Used to Formulate the Recommendations" type="picklist-choice">
      <fieldvalue value="Expert Consensus (Delphi)"/>
      <fieldvalue value="Expert Consensus (Nominal Group Technique)"/>
    </field>
    <field fieldid="145" ordby="545" id="414" name="Description of Methods Used to Formulate the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Question Formulation</strong></p>
<p>The maple syrup urine disease (MSUD) workgroup consisted of eight experienced metabolic dietitians who began the process by independently identifying over 40 practice areas where uncertainty and/or variation in practice existed. These were categorized and prioritized. Five topics were identified for evidence analysis and guideline development. Research questions for each topic were formulated in the PICO (population, intervention, comparison, and outcomes) format.</p>
<p><strong>Consensus Input and Evidence Summary</strong></p>
<p>Key information from all eligible evidence sources (scientific and gray literature) for each question was summarized on an evidence table. Many issues of concern to nutrition management were not addressed or were inconclusive from the combined sources. For these issues, expert input from nutrition and medical clinicians and researchers was sought using a Delphi survey, nominal group process meeting and a second-round Delphi survey. By systematically employing these techniques, the level of agreement with a specific practice statement was quantified. Also, input from the target population (patient and family) was included in the nominal group process. The final conclusion statement for each question represented a synthesis of evidence from scientific publications, gray literature, and Delphi and nominal group consensus techniques.</p>
<p><strong>Guideline Development</strong></p>
<p>Specific recommendations for nutrition management in each of the five topic areas were derived from the summaries, and each recommendation was rated with respect to strength (A = strong, B = fair, C = weak, D = consensus, E = insufficient evidence) and need for clinical action (I = imperative or II = conditional). See the &quot;Rating Scheme for the Strength of the Recommendations&quot; field.</p>
<p>These practice recommendations along with background and other information to support their implementation are contained in the MSUD Nutrition Management Guideline document.</p></div>"/>
    </field>
    <field fieldid="146" ordby="550" id="415" name="Rating Scheme for the Strength of the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Recommendation Ratings and Application</strong></p>
<table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Recommendation Ratings and Application&quot;>
    <tbody>
        <tr>
            <th valign=&quot;top&quot; colspan=&quot;3&quot;>Recommendation Rating</th>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot; style=&quot;width: 5%;&quot;>A</td>
            <td valign=&quot;top&quot;>Strong</td>
            <td valign=&quot;top&quot;>The benefits clearly exceed the harms (or the harms clearly exceed the benefits in the case of a strong negative recommendation); and the quality of the supporting evidence is excellent/good. In some clearly identified circumstances, strong recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits strongly outweigh the harms.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>B</td>
            <td valign=&quot;top&quot;>Fair</td>
            <td valign=&quot;top&quot;>The benefits exceed the harms (or the harms clearly exceed the benefits in the case of a negative recommendation), but the quality of evidence is not as strong as &quot;A&quot;. In some clearly identified circumstances, recommendations may be made based on lesser evidence when high-quality evidence is impossible to obtain and the anticipated benefits outweigh the harms.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>C</td>
            <td valign=&quot;top&quot;>Weak</td>
            <td valign=&quot;top&quot;>The quality of evidence that exists is suspect or well-done studies show little clear advantage for one recommendation over another.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>D</td>
            <td valign=&quot;top&quot;>Consensus</td>
            <td valign=&quot;top&quot;>Expert opinion supports the recommendation even though the available scientific evidence did not present consistent results, or controlled trials were lacking.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>E</td>
            <td valign=&quot;top&quot;>Insufficient Evidence</td>
            <td valign=&quot;top&quot;>There is a lack of pertinent evidence and this may be due to an unclear balance between benefits and harms.</td>
        </tr>
        <tr>
            <th valign=&quot;top&quot; colspan=&quot;3&quot;>Clinical Action/Application</th>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>I</td>
            <td valign=&quot;top&quot;>Imperative</td>
            <td valign=&quot;top&quot;>The recommendation is broadly applicable to the target population without conditions. An imperative recommendation can be stated in &quot;require,&quot; or &quot;must,&quot; or &quot;should achieve certain goals&quot; terminology.</td>
        </tr>
        <tr>
            <td class=&quot;Center&quot; valign=&quot;top&quot;>II</td>
            <td valign=&quot;top&quot;>Conditional</td>
            <td valign=&quot;top&quot;>The recommendation clearly defines a specific situation that limits its applicability. A conditional recommendation can be stated in &quot;if/then&quot; terminology.</td>
        </tr>
    </tbody>
</table>
<p class=&quot;Note&quot;>Adapted for this guideline from: American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics 2004; 114(3):874&amp;ndash;7.</p></div>"/>
    </field>
    <field fieldid="148" ordby="565" id="417" name="Cost Analysis" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div>"/>
    </field>
    <field fieldid="104" ordby="570" id="418" name="Method of Guideline Validation" type="picklist-choice">
      <fieldvalue value="External Peer Review"/>
    </field>
    <field fieldid="130" ordby="575" id="419" name="Description of Method of Guideline Validation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The final document was reviewed, using the Appraisal of Guidelines for Research and Evaluation (AGREE II) criteria by an external panel of metabolic dietitians, physicians and an expert in guideline development methodology who were not involved in the evidence analysis nor in the development phases of the maple syrup urine disease (MSUD) guideline.</p></div>"/>
    </field>
  </section>
  <section secid="424" ordby="600" name="Evidence Supporting the Recommendations">
    <field fieldid="139" ordby="610" id="426" name="Type of Evidence Supporting the Recommendations" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The type of supporting evidence is specifically stated for each recommendation (see the &quot;Major Recommendations&quot; field).</p></div>"/>
    </field>
  </section>
  <section secid="427" ordby="700" name="Benefits/Harms of Implementing the Guideline Recommendations">
    <field fieldid="152" ordby="705" id="428" name="Potential Benefits" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Implementing the recommendations would:</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Reduce variations in clinical practice and services across medical centers </li>
    <li>Guide practice decisions that integrate medical and nutrition management/therapy </li>
    <li>Provide clinicians with criteria to make recommendations for nutrition management or recommend other treatments to achieve outcomes </li>
    <li>Design quality nutrition care based on a patient's metabolic and/or genetic alteration </li>
    <li>Improve patient outcomes and clinician effectiveness </li>
    <li>Enhance patient quality of life, prevent untoward consequences and complications and reduce associated medical, educational and social costs. </li>
</ul></div>"/>
    </field>
    <field fieldid="153" ordby="710" id="429" name="Potential Harms" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Dietary restriction of the branched chain amino acids (BCAA) is complex and requires frequent monitoring and adjustment.</p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Inappropriate intake of medical food can impact growth, nutritional status and overall health. </li>
    <li>Excessive intake of foods with intact protein can raise BCAA and &amp;alpha;-ketoacids (BCKA) levels, cause metabolic decompensation, and have an impact on the central nervous system. </li>
    <li>Over-restriction of BCAA can impact growth and development and have very specific effects on various tissues of the body. </li>
    <li>During illness, catabolism increases the endogenous production of BCAA and puts the individual at risk for metabolic decompensation. Failure to adjust nutrient intake at this time, can be detrimental. </li>
    <li>Pregnancy in a woman with maple syrup urine disease (MSUD) involves not only the typical MSUD management, but also the increased needs of the pregnancy, the health of the fetus, the management of pregnancy-related illnesses and the rapid changes that occur after delivery. </li>
    <li>Liver transplantation may allow an individual with MSUD to consume a BCAA-unrestricted diet, but without nutritional counseling during the transition, nutrient needs may not be met.</li>
</ul>
<p>Lack of appropriate nutrition management can result in negative consequences. This can be the result of implementing only some of the recommendations, failing to monitor outcomes, and failing to adjust nutrient intake in response to growth or illness.</p></div>"/>
    </field>
  </section>
  <section secid="432" ordby="900" name="Qualifying Statements">
    <field fieldid="137" ordby="905" id="433" name="Qualifying Statements" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This nutrition management guideline is meant to serve as a framework for providing nutrition care to individuals with maple syrup urine disease (MSUD). It may not always be appropriate to use these guidelines. Individual circumstances and complicating conditions must be taken into consideration. The clinical judgment of the health care provider and patient preferences and values dictate treatment decisions. These nutrition management guidelines are provided with the express understanding that they do not establish or specify particular standards of care, whether legal, medical, or other.</p></div>"/>
    </field>
  </section>
  <section secid="434" ordby="1000" name="Implementation of the Guideline">
    <field fieldid="131" ordby="1010" id="436" name="Description of Implementation Strategy" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>An implementation strategy was not provided.</p></div>"/>
    </field>
    <field fieldid="117" ordby="1015" id="437" name="Implementation Tools" type="picklist-many">
      <fieldvalue value="Patient Resources"/>
    </field>
  </section>
  <section secid="439" ordby="1100" name="Institute of Medicine (IOM) National Healthcare Quality Report Categories">
    <field fieldid="50" ordby="1105" id="440" name="IOM Care Need" type="picklist-many">
      <fieldvalue value="Living with Illness"/>
      <fieldvalue value="Staying Healthy"/>
    </field>
    <field fieldid="51" ordby="1110" id="441" name="IOM Domain" type="picklist-many">
      <fieldvalue value="Effectiveness"/>
      <fieldvalue value="Patient-centeredness"/>
    </field>
  </section>
  <section secid="442" ordby="1200" name="Identifying Information and Availability">
    <field fieldid="97" ordby="1201" id="392" name="Bibliographic Source(s)" type="citation">
      <fieldvalue value="<table><tr><td>Frazier DM, Allgeier C, Homer C, Marriage BJ, Ogata B, Rohr F, Splett PL, Stembridge A, Singh RH. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metab. 2014 Jul;112(3):210-7. [72 references] <a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24881969&quot; target=&quot;_blank&quot;>PubMed</a></td></tr></table>"/>
    </field>
    <field fieldid="124" ordby="1205" id="443" name="Adaptation" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Not applicable: The guideline was not adapted from another source.</p></div>"/>
    </field>
    <field fieldid="128" ordby="1215" id="445" name="Date Released" type="text">
      <fieldvalue value="2014 Jul"/>
    </field>
    <field fieldid="158" ordby="1225" id="447" name="Guideline Developer(s)" type="orglist-p">
      <fieldvalue value="Genetic Metabolic Dietitians International &amp; Southeast Regional Newborn Screening and Genetics Consortium - Independent Expert Panel"/>
    </field>
    <field fieldid="125" ordby="1235" id="449" name="Source(s) of Funding" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The authors wish to acknowledge financial support from Health Resources and Services Administration (HRSA) (grant number #H46MC24090) and the MSUD Family Support Network.</p></div>"/>
    </field>
    <field fieldid="126" ordby="1240" id="450" name="Guideline Committee" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Maple Syrup Urine Disease (MSUD) Workgroup</p></div>"/>
    </field>
    <field fieldid="127" ordby="1245" id="451" name="Composition of Group That Authored the Guideline" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><em>Workgroup Members</em>: Dianne M. Frazier, Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA; Courtney Allgeier, Abbott Nutrition, Columbus, OH, USA; Caroline Homer, Specially for Children Subspecialists, Seton Healthcare Family, Austin, TX, USA; Barbara J. Marriage, Abbott Nutrition, Columbus, OH, USA; Beth Ogata, Department of Pediatrics, University of Washington, Seattle, WA, USA; Frances Rohr, Department of Genetics and Metabolism, Boston Children's Hospital, Boston, MA, USA; Patricia L. Splett, Food Science and Nutrition, University of Minnesota, St. Paul, MN, USA, Splett &amp;amp; Associates, Stanchfield, MN, USA; Adrya Stembridge, Division of Medical Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA; Rani H. Singh, Division of Medical Genetics, Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA</p></div>"/>
    </field>
    <field fieldid="147" ordby="1250" id="452" name="Financial Disclosures/Conflicts of Interest" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p><strong>Conflicts of Interest</strong></p>
<ul style=&quot;list-style-type: disc;&quot;>
    <li>Dianne Frazier &amp;mdash; received honoraria from Nutricia North America and Abbott Nutrition for consulting and lectures </li>
    <li>Courtney Allgeier &amp;mdash; employee of Abbott Nutrition </li>
    <li>Caroline Homer &amp;mdash; received honorarium for lecturing from Abbott Nutrition </li>
    <li>Barbara Marriage &amp;mdash; employee of Abbott Nutrition </li>
    <li>Beth Ogata &amp;mdash; none declared </li>
    <li>Frances Rohr &amp;mdash; none declared </li>
    <li>Patricia Splett &amp;mdash; none declared </li>
    <li>Adrya Stembridge &amp;mdash; received funding from HRSA </li>
    <li>Rani Singh &amp;mdash; received funding from HRSA </li>
</ul></div>"/>
    </field>
    <field fieldid="120" ordby="1256" id="393" name="Guideline Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This is the current release of the guideline.</p>
<p>This guideline meets NGC's 2013 (revised) inclusion criteria.</p></div>"/>
    </field>
    <field fieldid="118" ordby="1260" id="454" name="Guideline Availability" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Electronic copies: Available from the <a href=&quot;http://www.sciencedirect.com/science/article/pii/S1096719214001607&quot; title=&quot;Molecular Genetics and Metabolism Web site&quot;>Molecular Genetics and Metabolism Web site</a>.</p></div>"/>
    </field>
    <field fieldid="119" ordby="1265" id="455" name="Availability of Companion Documents" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>The HTML version of the guideline, with additional tables and other information, is available from the <a href=&quot;https://southeastgenetics.org/ngp/guidelines.php/59/MSUD%20Nutrition%20Guidelines/Version%201.46&quot; title=&quot;Southeast Regional Newborn Screening and Genetics Consortium Web site&quot;>Southeast Regional Newborn Screening and Genetics Consortium Web site</a>.</p></div>"/>
    </field>
    <field fieldid="143" ordby="1275" id="457" name="Patient Resources" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>Learning objectives for patients and family are available from the <a href=&quot;https://southeastgenetics.org/ngp/guidelines.php/59/res/0/0/MSUD%20Nutrition%20Guidelines/Version%201.46/Resources#Overview&quot; title=&quot;Southeast Regional Newborn Screening and Genetics Consortium Web site&quot;>Southeast Regional Newborn Screening and Genetics Consortium Web site</a>.</p>
<p class=&quot;Disclaimer&quot;>Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.</p></div>"/>
    </field>
    <field fieldid="142" ordby="1280" id="458" name="NGC Status" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary was completed by ECRI Institute on January 7, 2015. The information was verified by the guideline developer on March 13, 2015.</p></div>"/>
    </field>
    <field fieldid="141" ordby="1290" id="460" name="Copyright Statement" type="text">
      <fieldvalue value="<div class=&quot;content_para&quot;><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div>"/>
    </field>
  </section>
  <section secid="99999" ordby="99999" name="Disclaimer">
    <field fieldid="99999" ordby="99999" id="99999" name="NGC Disclaimer" type="text">
      <fieldvalue value="<p>The National Guideline Clearinghouse (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href=&quot;/help-and-about/summaries/inclusion-criteria&quot;>NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p>"/>
    </field>
  </section>
</version><!--
     FILE ARCHIVED ON 23:39:11 Oct 02, 2017 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 23:39:24 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 76.637 (3)
  esindex: 0.008
  captures_list: 93.521
  CDXLines.iter: 12.508 (3)
  PetaboxLoader3.datanode: 62.374 (4)
  exclusion.robots: 0.26
  exclusion.robots.policy: 0.247
  RedisCDXSource: 0.993
  PetaboxLoader3.resolve: 208.034
  load_resource: 246.351
-->